News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,674 Results
Type
Article (42176)
Company Profile (255)
Press Release (672242)
Multimedia
Podcasts (87)
Webinars (15)
Section
Business (206581)
Career Advice (2099)
Deals (35723)
Drug Delivery (110)
Drug Development (82277)
Employer Resources (173)
FDA (16529)
Job Trends (15169)
News (349974)
Policy (33614)
Tag
Academia (2634)
Accelerated approval (10)
Adcomms (24)
Allergies (99)
Alliances (50332)
ALS (113)
Alzheimer's disease (1478)
Antibody-drug conjugate (ADC) (163)
Approvals (16514)
Artificial intelligence (319)
Autoimmune disease (30)
Automation (18)
Bankruptcy (367)
Best Places to Work (11770)
BIOSECURE Act (20)
Biosimilars (125)
Biotechnology (178)
Bladder cancer (95)
Brain cancer (34)
Breast cancer (370)
Cancer (2920)
Cardiovascular disease (224)
Career advice (1757)
Career pathing (32)
CAR-T (190)
CDC (33)
Cell therapy (510)
Cervical cancer (23)
Clinical research (67652)
Collaboration (1039)
Company closure (3)
Compensation (687)
Complete response letters (24)
COVID-19 (2690)
CRISPR (59)
C-suite (327)
Cystic fibrosis (114)
Data (3008)
Decentralized trials (2)
Denatured (22)
Depression (65)
Diabetes (369)
Diagnostics (6483)
Digital health (23)
Diversity (9)
Diversity, equity & inclusion (45)
Drug discovery (141)
Drug pricing (138)
Drug shortages (33)
Duchenne muscular dystrophy (127)
Earnings (88087)
Editorial (43)
Employer branding (22)
Employer resources (149)
Events (115095)
Executive appointments (853)
FDA (18197)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (944)
Gene editing (135)
Generative AI (24)
Gene therapy (391)
GLP-1 (884)
Government (4854)
Grass and pollen (5)
Guidances (181)
Healthcare (19187)
HIV (43)
Huntington's disease (31)
IgA nephropathy (40)
Immunology and inflammation (156)
Immuno-oncology (10)
Indications (39)
Infectious disease (2871)
Inflammatory bowel disease (152)
Inflation Reduction Act (11)
Influenza (64)
Intellectual property (120)
Interviews (337)
IPO (16674)
IRA (46)
Job creations (3790)
Job search strategy (1483)
Kidney cancer (13)
Labor market (52)
Layoffs (516)
Leadership (22)
Legal (8120)
Liver cancer (81)
Longevity (12)
Lung cancer (409)
Lymphoma (210)
Machine learning (11)
Management (58)
Manufacturing (401)
MASH (95)
Medical device (13661)
Medtech (13666)
Mergers & acquisitions (19765)
Metabolic disorders (936)
Multiple sclerosis (101)
NASH (22)
Neurodegenerative disease (124)
Neuropsychiatric disorders (35)
Neuroscience (2181)
NextGen: Class of 2025 (6644)
Non-profit (4598)
Now hiring (48)
Obesity (485)
Opinion (238)
Ovarian cancer (103)
Pain (112)
Pancreatic cancer (120)
Parkinson's disease (191)
Partnered (22)
Patents (300)
Patient recruitment (164)
Peanut (52)
People (58300)
Pharmaceutical (64)
Pharmacy benefit managers (23)
Phase I (21039)
Phase II (29754)
Phase III (22256)
Pipeline (1648)
Policy (213)
Postmarket research (2617)
Preclinical (8984)
Press Release (67)
Prostate cancer (141)
Psychedelics (39)
Radiopharmaceuticals (256)
Rare diseases (471)
Real estate (5989)
Recruiting (67)
Regulatory (23187)
Reports (50)
Research institute (2377)
Resumes & cover letters (360)
Rett syndrome (9)
RNA editing (9)
RSV (53)
Schizophrenia (90)
Series A (159)
Series B (109)
Service/supplier (12)
Sickle cell disease (64)
Special edition (20)
Spinal muscular atrophy (151)
Sponsored (33)
Startups (3642)
State (2)
Stomach cancer (16)
Supply chain (80)
Tariffs (64)
The Weekly (63)
Vaccines (815)
Venture capital (54)
Weight loss (319)
Women's health (49)
Worklife (16)
Date
Today (71)
Last 7 days (365)
Last 30 days (1895)
Last 365 days (31590)
2025 (16958)
2024 (35614)
2023 (40444)
2022 (51622)
2021 (56260)
2020 (54757)
2019 (47414)
2018 (35723)
2017 (32582)
2016 (32089)
2015 (38127)
2014 (31806)
2013 (26776)
2012 (28973)
2011 (29659)
2010 (27723)
Location
Africa (757)
Alabama (61)
Alaska (7)
Arizona (248)
Arkansas (13)
Asia (38865)
Australia (6407)
California (7468)
Canada (2390)
China (681)
Colorado (322)
Connecticut (320)
Delaware (193)
Europe (83968)
Florida (1123)
Georgia (248)
Hawaii (1)
Idaho (61)
Illinois (646)
India (28)
Indiana (367)
Iowa (16)
Japan (230)
Kansas (110)
Kentucky (30)
Louisiana (14)
Maine (64)
Maryland (1029)
Massachusetts (5569)
Michigan (247)
Minnesota (453)
Mississippi (3)
Missouri (94)
Montana (28)
Nebraska (25)
Nevada (80)
New Hampshire (69)
New Jersey (2080)
New Mexico (28)
New York (2093)
North Carolina (1089)
North Dakota (9)
Northern California (3285)
Ohio (236)
Oklahoma (16)
Oregon (34)
Pennsylvania (1615)
Puerto Rico (17)
Rhode Island (36)
South America (1129)
South Carolina (34)
South Dakota (1)
Southern California (2793)
Tennessee (127)
Texas (1127)
United States (27716)
Utah (219)
Virginia (187)
Washington D.C. (74)
Washington State (635)
West Virginia (4)
Wisconsin (66)
714,674 Results for "eli lilly canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Alzheimer’s disease
Lilly Gets FDA Label Update for Alzheimer’s Drug To Mitigate Safety Concerns
The FDA will allow a new dosing schedule for Eli Lilly’s Alzheimer’s drug Kisunla that could lessen a known side effect of the monoclonal antibody drug class that has led to several deaths.
July 9, 2025
·
2 min read
·
Annalee Armstrong
Weight Loss
Lilly Takes Victory Lap on Oral Weight Loss Drug as Analysts Spot Safety Crack
While Eli Lilly brushed off concerns about gastrointestinal side effects for oral weight loss candidate orforglipron, analysts from William Blair worried that adverse events are not tapering off as expected.
June 23, 2025
·
5 min read
·
Annalee Armstrong
Weight loss
Lilly’s Antibody Protects Patients From Losing Muscle While Taking Novo’s Wegovy
Eli Lilly’s bimagrumab led to weight loss that was due almost entirely to fat reduction when combined with semaglutide, marketed by rival Novo Nordisk as Wegovy. BMO Capital Markets called the data “impressive” while raising concerns about the antibody’s safety profile.
June 24, 2025
·
2 min read
·
Tristan Manalac
Obesity
Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy
In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink analysts say confirm the GLP-1 drug’s edge in the closely watched market race.
May 12, 2025
·
2 min read
·
Tristan Manalac
Obesity
Lilly Inks Deal Worth up to $870M To Develop Long-Acting GLP-1 Obesity Drugs
Eli Lilly joins up with Camurus to make long-acting versions of the pharma’s obesity and diabetes drugs, joining the industry’s growing pipeline of programs that are differentiated by the frequency of dosing.
June 4, 2025
·
2 min read
·
Nick Paul Taylor
Manufacturing
After Phase III Win, Lilly Promises to Manufacture Weight-Loss Pill in US
President Donald Trump in February threatened top pharma leaders, including Eli Lilly CEO David Ricks, with tariffs unless they reshore their manufacturing operations.
April 21, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases
June 2, 2025
·
3 min read
Legal
Lilly’s Fight to Stop Zepbound Knockoffs Leads to Lawsuit Against Indianapolis Spa
Eli Lilly says Indianapolis-based Premier Weight Loss is cracking open auto-injector pens containing its blockbuster drug and repackaging them into separate doses.
April 7, 2025
·
4 min read
·
Annalee Armstrong
Earnings
Lilly Unfazed as CVS Picks Novo’s Side in Obesity Market Battle
Eli Lilly CEO David Ricks is confident that weight loss med Zepbound is gaining market share at the expense of Wegovy, even as its rival strikes deals with CVS and Hims & Hers pharmacies.
May 1, 2025
·
3 min read
·
Annalee Armstrong
Weight loss
Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena
The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to develop long-acting versions of molecules against GLP-1 and other incretins.
June 11, 2025
·
1 min read
·
Annalee Armstrong
1 of 71,468
Next
